80 related articles for article (PubMed ID: 16256294)
1. Long term follow-up of c-myc, p53 and proliferation measurements in malignant melanoma.
Ross DA; Laing JH; Sanders R; Wilson GD
Eur J Surg Oncol; 2006 Feb; 32(1):80-4. PubMed ID: 16256294
[TBL] [Abstract][Full Text] [Related]
2. A prospective analysis of c-myc oncoprotein levels as a prognostic marker in malignant melanoma.
Ramsden AJ; Grover R; Chana J; Tulley P; Sanders R; Wilson GD
J Plast Reconstr Aesthet Surg; 2007; 60(6):626-30. PubMed ID: 17485049
[TBL] [Abstract][Full Text] [Related]
3. Measurement of c-myc oncogene expression provides an accurate prognostic marker for acral lentiginous melanoma.
Grover R; Chana J; Grobbelaar AO; Hudson DA; Forder M; Wilson GD; Sanders R
Br J Plast Surg; 1999 Mar; 52(2):122-6. PubMed ID: 10434891
[TBL] [Abstract][Full Text] [Related]
4. Expression of c-myc oncoprotein represents a new prognostic marker in cutaneous melanoma.
Ross DA; Wilson GD
Br J Surg; 1998 Jan; 85(1):46-51. PubMed ID: 9462382
[TBL] [Abstract][Full Text] [Related]
5. Flow cytometric analysis of p53 oncoprotein expression in cutaneous melanoma.
Ross DA; Wilson GD
Br J Surg; 1997 Jun; 84(6):803-7. PubMed ID: 9189093
[TBL] [Abstract][Full Text] [Related]
6. The clinical significance of c-myc oncogene expression in melanomas of the scalp.
Chana JS; Grover R; Wilson GD; Hudson DA; Forders M; Sanders R; Grobbelaar AO
Br J Plast Surg; 1998 Apr; 51(3):191-4. PubMed ID: 9664877
[TBL] [Abstract][Full Text] [Related]
7. Use of oncogene expression as an independent prognostic marker for primary melanoma.
Grover R; Pacifico MD; Wilson GD; Sanders R
Ann Plast Surg; 2003 Feb; 50(2):183-7. PubMed ID: 12567057
[TBL] [Abstract][Full Text] [Related]
8. Use of the OM-11-906 monoclonal antibody for determining p62 c-myc expression by flow cytometry in relation to prognosis in colorectal cancer.
Rowley S; Carpenter R; Newbold KM; Gearty J; Keighley MR; Donovan IA; Neoptolemos JP
Eur J Surg Oncol; 1991 Aug; 17(4):370-8. PubMed ID: 1874294
[TBL] [Abstract][Full Text] [Related]
9. [DNA content analysis and detection of c-myc and p53 products using flow cytometry in resected lung cancer cases].
Chiba W; Sawai S; Ikeda S; Morimoto K; Wazawa H; Hanawa T; Yamashita N; Matsui T; Hatakenaka R; Matsubara Y
Gan To Kagaku Ryoho; 1994 May; 21 Suppl 1():108-16. PubMed ID: 8203922
[TBL] [Abstract][Full Text] [Related]
10. [Immunohistochemical study of the predictive value of oncoproteins p53, HER-2 and c-myc during radiotherapy for squamous cell carcinoma of the cervix].
Gasparian NA; Pozharisskiĭ KM; Zharinov GM; Vinokurov VL; Kuznetsova ME; Neklasova NIu
Vopr Onkol; 2007; 53(4):439-44. PubMed ID: 17969407
[TBL] [Abstract][Full Text] [Related]
11. Frequent upregulation of MYC in plasma cell leukemia.
Chiecchio L; Dagrada GP; White HE; Towsend MR; Protheroe RK; Cheung KL; Stockley DM; Orchard KH; Cross NC; Harrison CJ; Ross FM;
Genes Chromosomes Cancer; 2009 Jul; 48(7):624-36. PubMed ID: 19396865
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of the Epstein-Barr virus, p53, Bcl-2, and survivin in nasopharyngeal cancer.
Yip KW; Shi W; Pintilie M; Martin JD; Mocanu JD; Wong D; MacMillan C; Gullane P; O'Sullivan B; Bastianutto C; Liu FF
Clin Cancer Res; 2006 Oct; 12(19):5726-32. PubMed ID: 17020977
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
14. Occurrence and expression of p53 suppressor gene and c-Myc oncogene in dog eyelid tumors.
Lopes RA; Cardoso TC; Luvizotto MC; de Andrade AL
Vet Ophthalmol; 2010 Mar; 13(2):69-75. PubMed ID: 20447023
[TBL] [Abstract][Full Text] [Related]
15. c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma.
Chana JS; Wilson GD; Cree IA; Alexander RA; Myatt N; Neale M; Foss AJ; Hungerford JL
Br J Ophthalmol; 1999 Jan; 83(1):110-4. PubMed ID: 10209447
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometric quantitation of C-myc and P53 proteins in bovine papillomavirus type 1-transformed primary mouse fibroblasts.
Agrawal RS; Agrawal YP; Mäntyjärvi RA
Cytometry; 1994 Nov; 17(3):237-45. PubMed ID: 7851159
[TBL] [Abstract][Full Text] [Related]
17. The correlation between cell surface markers and clinical features in choroidal malignant melanomas.
Lawry J; Currie Z; Smith MO; Rennie IG
Eye (Lond); 1999 Jun; 13 ( Pt 3a)():301-8. PubMed ID: 10624422
[TBL] [Abstract][Full Text] [Related]
18. Detection of human papillomavirus and relevant tumor suppressors and oncoproteins in laryngeal tumors.
Manjarrez ME; Ocadiz R; Valle L; Pacheco C; Marroquin A; De la Torre C; Selman M; Gariglio P
Clin Cancer Res; 2006 Dec; 12(23):6946-51. PubMed ID: 17145812
[TBL] [Abstract][Full Text] [Related]
19. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
Logullo AF; Lopes AB; Nonogaki S; Soares FA; Netto MM; Nishimoto IN; Brentani MM
Oncol Rep; 2007 Jul; 18(1):121-6. PubMed ID: 17549356
[TBL] [Abstract][Full Text] [Related]
20. Gene-hypermutated isoforms of MYC protein: Tumour-suppressor P-53 protective-initiation of apoptosis that normally prevents Burkitt's lymphoma tumorigenesis can be enhanced.
Wiseman A
Med Hypotheses; 2006; 66(5):1046-7. PubMed ID: 16413684
[No Abstract] [Full Text] [Related]
[Next] [New Search]
